About Conatus Pharmaceuticals (NASDAQ:CNAT)
Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company was founded in 2005 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CNAT
CUSIPN/A
Phone858-376-2600
Debt
Debt-to-Equity Ratio0.47%
Current Ratio2.82%
Quick Ratio2.82%
Price-To-Earnings
Trailing P/E Ratio-5.85
Forward P/E Ratio-5.03
P/E GrowthN/A
Sales & Book Value
Annual Sales$35.38 million
Price / Sales3.03
Cash FlowN/A
Price / CashN/A
Book Value$0.93 per share
Price / Book3.84
Profitability
EPS (Most Recent Fiscal Year)($0.61)
Net Income$-17,390,000.00
Net Margins-49.17%
Return on Equity-61.58%
Return on Assets-19.67%
Miscellaneous
Employees35
Outstanding Shares30,060,000
Conatus Pharmaceuticals (NASDAQ:CNAT) Frequently Asked Questions
What is Conatus Pharmaceuticals' stock symbol?
Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT."
How were Conatus Pharmaceuticals' earnings last quarter?
Conatus Pharmaceuticals (NASDAQ:CNAT) issued its quarterly earnings results on Wednesday, March, 7th. The biotechnology company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.02. The biotechnology company had revenue of $8.80 million for the quarter, compared to analyst estimates of $9.60 million. Conatus Pharmaceuticals had a negative return on equity of 61.58% and a negative net margin of 49.17%. View Conatus Pharmaceuticals' Earnings History.
When is Conatus Pharmaceuticals' next earnings date?
What price target have analysts set for CNAT?
7 Wall Street analysts have issued twelve-month price objectives for Conatus Pharmaceuticals' shares. Their forecasts range from $4.30 to $20.00. On average, they expect Conatus Pharmaceuticals' share price to reach $11.9988 in the next twelve months. View Analyst Ratings for Conatus Pharmaceuticals.
Who are some of Conatus Pharmaceuticals' key competitors?
Some companies that are related to Conatus Pharmaceuticals include Tyme Technologies (TYME), VBI Vaccines (VBIV), Verastem (VSTM), Tocagen (TOCA), Evolus (EOLS), Menlo Therapeutics (MNLO), Scpharmaceuticals (SCPH), Marinus Pharmaceuticals (MRNS), Ra Pharmaceuticals (RARX), POXEL (PXXLF), Xoma (XOMA), Teligent (TLGT), Summit Therapeutics (SMMT), Spero Therapeutics (SPRO), Zafgen (ZFGN), Nabriva Therapeutics (NBRV), Protagonist Therapeutics (PTGX) and Kamada (KMDA).
Who are Conatus Pharmaceuticals' key executives?
Conatus Pharmaceuticals' management team includes the folowing people:
- Dr. Steven J. Mento, Co-Founder, CEO, Pres & Director (Age 66)
- Dr. Alfred P. Spada Ph.D., Co-Founder, Chief Scientific Officer and Exec. VP of R&D (Age 60)
- Dr. David T. Hagerty M.D., Exec. VP of Clinical Devel. (Age 63)
- Dr. Keith W. Marshall MBA, Ph.D., Exec. VP, COO & CFO
- Ms. Michelle L. Vandertie, Principal Accounting Officer & VP of Fin. (Age 54)
Has Conatus Pharmaceuticals been receiving favorable news coverage?
News headlines about CNAT stock have trended somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Conatus Pharmaceuticals earned a media sentiment score of 0.23 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 44.22 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Conatus Pharmaceuticals?
Shares of CNAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Conatus Pharmaceuticals' stock price today?
One share of CNAT stock can currently be purchased for approximately $3.57.
How big of a company is Conatus Pharmaceuticals?
Conatus Pharmaceuticals has a market capitalization of $107.31 million and generates $35.38 million in revenue each year. The biotechnology company earns $-17,390,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. Conatus Pharmaceuticals employs 35 workers across the globe.
How can I contact Conatus Pharmaceuticals?
Conatus Pharmaceuticals' mailing address is 16745 WEST BERNARDO DRIVE Suite 200, San Diego CA, 92127. The biotechnology company can be reached via phone at 858-376-2600 or via email at [email protected]
MarketBeat Community Rating for Conatus Pharmaceuticals (CNAT)
MarketBeat's community ratings are surveys of what our community members think about Conatus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNAT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Conatus Pharmaceuticals (NASDAQ:CNAT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Conatus Pharmaceuticals in the last 12 months. Their average twelve-month price target is $11.9988, suggesting that the stock has a possible upside of 236.10%. The high price target for CNAT is $20.00 and the low price target for CNAT is $4.30. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $11.9988 | $13.67 | $14.00 | $16.1667 |
| Price Target Upside: | 236.10% upside | 114.26% upside | 205.01% upside | 187.66% upside |
Conatus Pharmaceuticals (NASDAQ:CNAT) Consensus Price Target History
Conatus Pharmaceuticals (NASDAQ:CNAT) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Conatus Pharmaceuticals (NASDAQ:CNAT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Conatus Pharmaceuticals (NASDAQ CNAT) News Headlines
| Source: |
|
Conatus Pharmaceuticals (NASDAQ:CNAT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Conatus Pharmaceuticals (NASDAQ:CNAT) Income Statement, Balance Sheet and Cash Flow Statement
Conatus Pharmaceuticals (NASDAQ CNAT) Stock Chart for Saturday, April, 21, 2018
Loading chart…
